Most Indian pharmaceutical companies treat Africa and Southeast Asia as afterthoughts — secondary export markets useful for absorbing manufacturing capacity. Ajanta Pharma, founded in Mumbai in 1973, built its entire identity around them. The result is a $560 million branded-generics company that has turned overlooked geographies into its greatest competitive advantage, operating across more than 30 countries with deep expertise in ophthalmology, dermatology, and cardiology.
Ajanta’s founding insight was deceptively simple: millions of patients across Africa and Asia need affordable, high-quality medicines, but the multinational pharma companies have little incentive to build the physician relationships, regulatory dossiers, and distribution networks required to serve them. Ajanta stepped into that gap. Over five decades, the company established branded-generics franchises across more than 30 countries in sub-Saharan Africa, Southeast Asia, and the Middle East — markets where the Ajanta name carries genuine physician trust.
This is not contract manufacturing or commodity exporting. Ajanta registers its own brands, deploys its own field forces, and builds direct relationships with prescribers. In markets like Nigeria, the Philippines, and Iraq, Ajanta products are household names among healthcare professionals. In FY 2025, the combined Africa and Asia business contributed roughly 41% of total revenue — a share that most Indian pharma companies cannot match from any single international region.
The strategy carries inherent risks: currency volatility, political instability, and logistical complexity. But it also means Ajanta competes where few others choose to, earning branded margins in markets where the competitive field is thin. It is a structural advantage that compounds over time as relationships deepen and product portfolios expand.
If emerging markets represent Ajanta’s origin story, India represents its growth engine. The domestic business accounts for approximately 35% of revenue and is concentrated in high-growth specialty segments: ophthalmology, dermatology, cardiology, and pain management. These are not commodity-driven therapy areas — they demand specialised field forces, physician education, and differentiated formulations.
In ophthalmology, Ajanta has built one of the strongest branded portfolios among Indian pharmaceutical companies, offering sterile eye-drop formulations that require precision manufacturing. In dermatology, the company competes against much larger players by focusing on niche formulations rather than broad-spectrum offerings. The cardiology division targets India’s growing chronic-disease burden with a portfolio spanning hypertension, dyslipidemia, and diabetes management.
This domestic positioning is deliberate. Rather than competing across every therapeutic category, Ajanta chose depth over breadth — becoming a significant player in a handful of high-margin specialties. More than 850 scientists work in the company’s R&D operations, accounting for approximately 7% of revenue, developing complex formulations in tablets, capsules, ophthalmic sterile preparations, and ointments.
Ajanta entered the United States market later than many Indian generics companies, but it did so with characteristic focus. Rather than filing hundreds of abbreviated new drug applications across commodity molecules, Ajanta targeted niche opportunities — complex generics and speciality dosage forms where competition is lower and margins are more defensible. By FY 2025, the company had 27 products on the US market and approximately 40 development projects in its research programme.
Two manufacturing facilities carry US FDA registration: the formulation plants at Dahej in Gujarat and Paithan in Maharashtra. Both received Establishment Inspection Reports and are dedicated primarily to supplying the US market. The US business contributed roughly 24% of FY 2025 revenue — a meaningful contribution, but not an overwhelming dependence on a single geography.
This balance matters. Unlike companies that derive 50% or more of revenue from US generics — exposing themselves to pricing pressure, channel consolidation, and regulatory risk — Ajanta treats the US as one pillar of a three-legged strategy alongside India and emerging markets. No single geography accounts for more than 41% of revenue, which gives the company resilience that pure-play US generics companies often lack.
Ajanta’s geographic diversification is its defining characteristic. The branded-generics business across Africa and Asia accounts for 41% of revenue, India contributes 35%, and the US generics business adds 24%. The company operates seven manufacturing facilities across India and has over 1,400 products registered in various countries, with an equal number under regulatory review. More than 9,600 employees support operations spanning research, manufacturing, and commercial functions across four continents.
Ajanta operates seven manufacturing facilities across India, with plants at Dahej (Gujarat), Paithan, Waluj, Chikalthana, and Chittegaon (Maharashtra), Guwahati (Assam), and Pithampur (Madhya Pradesh). Two of these carry US FDA registration. The Dahej and Paithan facilities are dedicated primarily to the US market, producing complex oral solid dosages, ophthalmic sterile formulations, and speciality products. The remaining plants serve the company’s domestic and emerging-market businesses, manufacturing across a range of dosage forms including tablets, capsules, liquids, ointments, and sterile eye drops.
Sources: Ajanta Pharma Limited Annual Reports FY2020–21 through FY2024–25. Ajanta Pharma Investor Presentations Q4 FY2025 and Q1 FY2026. US FDA facility registration data. Indian patent office records.